Comments
Drug major Dr Reddy’s Laboratories today said the US health regulator had issued four observations after inspecting its active pharmaceutical ingredients (API) facility in Telangana. “The audit of our API Hyderabad plant 1 at Jinnaram Mandal, Medak district, Telangana, by the USFDA has been completed today. We have been issued a Form 483 with four observations, which will be addressed comprehensively within stipulated time,” Dr Reddy’s said in a regulatory filing.
According to the USFDA, a Form 483 is issued to a firm’s management at the conclusion of an inspection when investigator has observed any condition that in its judgement may constitute a violation of the Food Drug and Cosmetic (FD&C) Act and related Acts. It notifies the company’s management of objectionable conditions. Dr Reddy’s shares were trading 1.71 per cent down at Rs 2,145.95 on the BSE.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.